Maxim Reaffirms Celsion (CLSN) at 'Buy' as OVATION Study Safety Review Completed
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
- JPMorgan (JPM) Reports Q4 EPS of $1.71
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Maxim affirms Celsion Corp. (Nasdaq: CLSN) with a Buy rating and $4 price target after the company announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first three patient cohorts in the ongoing Phase Ib OVATION Study.
Analyst Jason McCarthy noted the following today:
- Data from the first six patients (Cohorts 1 and 2) demonstrated that one patient experienced a complete response, two had partial responses, and three had stable disease. In addition, the biological marker of ovarian cancer, CA-125, was decreased by over 95%. A decrease of 50% is considered "good" and a decrease over 95% is considered "excellent."
- Cohort three (N=3) has been treated, and the last cohort is now enrolling. Top-line data, including immune response data, is expected in 1Q17.
- Conclusion. Clearing the safety hurdle for an IL-12 based therapy is critical given the potential for toxicity. While we await data for ThermoDox in primary liver cancer (interim data late 2018), GEN-1 continues to generate newsflow in immune-oncology, which we believe represents incremental catalysts for the stock.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Tiffany & Co. (TIF) to Market Perform; Demand Trends Stabilizing
- UPDATE: Seaport Global Securities Upgrades Toro (TTC) to Buy
- BMO Capital Cuts Price Target on Ritchie Bros. Auctioneers (RBA) to $33
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!